X

Trial Profile

A Phase 1b, Open-Label, Dose Escalation Study of ADG116 in Combination With Pembrolizumab (Anti-PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 29 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADG 116 (Primary) ; Pembrolizumab (Primary)
Indications Solid tumours
Focus Adverse reactions; Proof of concept
Acronyms KEYNOTE C97
Sponsors Adagene

Most Recent Events

20 Apr 2023 Status changed from recruiting to completed.
10 Nov 2022 According to an Adagene media release, data from the trial were presented at the Society for Immunotherapy of Cancer 37th Annual Meeting (SITC 2022).
10 Nov 2022 Results presented in an Adagene media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com